Document Preview Unavailable

Cost-Effectiveness Analysis of First-Line FOLFIRI Combined With Cetuximab or Bevacizumab in Patients With RAS Wild-Type Left-Sided Metastatic Colorectal Cancer

Han Jiaqi; Xiao Desheng; Tan Chongqing; Zeng Xiaohui; Hu Huabin; et al.  Cancer Control Vol. 27, Iss. 1,  (Jan 2020).

You might have access to this document